#ACR25 Abstr#1608 10! 10! Across the board. 2-yr data from RCT + Open Label showed frequency of both airway and non-airway features of #EGPA improved with Benralizumab/Mepolizumab. Provides assurance to use more in real-world @RheumNow https://t.co/i78xXojGja

• https://x.com/Yuz6Yusof/status/1982897181272289562/photo/1

#ACR25 Abstr#1537 Beyond T-cell malignancy, we should be vigilant re: Local immune effector cell-associated toxicity syndrome (LICATS) with CAR-T. - Mostly afect skin & kidneys - Med time of onset 10 days; duration 11 days -Most LICATS were mild & without sequelae @RheumNow https://t.co/EnAWL936oh

• https://x.com/Yuz6Yusof/status/1982894724118917460/photo/1

So who with inflamm arthralgias might benefit from abatacept, in terms of delaying RA onset? ALTO study (APIPPRA continuation) 1y abatacept then follow If autoAb x5 (RF, ACPA IgG, IgA, anti-CarP, AAPA): sustained delay of RA If not: benefit only on Rx #ACR25 ABST1678 @RheumNow https://t.co/3Pc5ZLzVf6

• https://x.com/drdavidliew/status/1982890389179896280/photo/1
• https://x.com/drdavidliew/status/1982890389179896280/photo/1
• https://x.com/drdavidliew/status/1982890389179896280/photo/1

Early TNFi treatment leads to -Less D2T at 5 yrs -More sustained remission at 10yrs -Less bDMARD escalation at 5yrs -More DMARD free remission at 5yrs and 10 yrs -20% reduction annual healths costs -11 mo delay in ttmt escalation Safety data were not presented #ACR25 https://t.co/jPMGUGPtqP

• https://x.com/AurelieRheumo/status/1982886011811111053/photo/1
• https://x.com/AurelieRheumo/status/1982886011811111053/photo/1

SELECT-COMPARE RA UPA vs. ADA What do we learn from 7 years data? Not much Patients who did well on the first drug, keep doing well Patients who required switching for primary failure don't do as well, w/ 26% pts reaching DAS remission in UPA + MTX vs. 16% in ADA + MTX gp No https://t.co/JLUTRZuZOm

• https://x.com/AurelieRheumo/status/1982883419899195532/photo/1
• https://x.com/AurelieRheumo/status/1982883419899195532/photo/1
• https://x.com/AurelieRheumo/status/1982883419899195532/photo/1

In case you missed it in @ACR_Journals: HCQ for 1y does not prevent RA development in people with CCP3 >2x ULN, either: - during 1y of treatment - in 2y follow-up https://t.co/gtzNiSmutb but StopRA will give us plenty of insights - data is never wasted #ACR25 ABST1674 @RheumNow https://t.co/DDZib5VGtX

• A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid art…
• https://x.com/drdavidliew/status/1982874509758902603/photo/1

SELECT-COMPARE (upadacitinib vs adallimumab in mod-severe RA, no CV enrichment) 7y data: safety profiles very similar, except for: - zoster - CK rise - lymphopenia - hepatic disorder In the general RA population, no new JAKi safety signals #ACR25 ABST1676 @RheumNow https://t.co/BA2JxONGfa

• https://x.com/drdavidliew/status/1982882215160885563/photo/1

Start strong, stay strong. With early anti-TNF induction (vs csDMARD T2T) - At 5 yrs: D2T RA in <1% vs 7% (OR 0.11, p=0.03) Drug-free remission 13% vs 6% (p=0.049) - At 10 yrs: more sustained remission (62% vs 45%) & fewer multi-MoA failures. @RheumNow #ACR25 Abstract #1677

What is the secret of a VNS RCT that works in RA? => Implant the device! RESET-RA RCT Sham controlled 3mo Then open label in active arm for 66mo 40% pts IR to >=3 bioDMARDs ACR 20 3 mo 42% vs. 19% CDAI LDA 27% vs. 11% 82% TNF IR pt had no change in treatment over 12mo 99% https://t.co/lfxa4YXUB4

• https://x.com/AurelieRheumo/status/1982878622647230939/photo/1
• https://x.com/AurelieRheumo/status/1982878622647230939/photo/1
• https://x.com/AurelieRheumo/status/1982878622647230939/photo/1

Implantable vagal stimulator led to benefit in TNF-inadequate responder RA in this sham-controlled double-blind RCT (RESET-RA study) - 82% off b/tsDMARDs at 12mo - also with benefit to control group after crossover at 3mo to an active device #ACR25 1675 @RheumNow https://t.co/yYwWCKm6HF

• https://x.com/drdavidliew/status/1982878593199026656/photo/1

Did we need a 2nd Interception RCT of HCQ in Pre-RA? Unsure but in any case, it does not work either STOPRA CCP3+>=2 ind 71 HCQ and 74 PBO 36 months RA conversion Dr Deane's take: "probably wrong drug rather than wrong timing" #ACR25 @RheumNow #ABSTRACT1674 https://t.co/jysdo8iz7v

• https://x.com/AurelieRheumo/status/1982874833257152964/photo/1

#ACR25 SMILE RCT of Incomplete #SLE (ANA+ but not meeting SLICC) showed HCQ didn’t slow down SLE progression. But multiplex arrays showed reduction in autoantibodies with HCQ that were distinct from abs assoc. w progression. Would biomarker endpoints be the answer? @RheumNow https://t.co/XcvacgObVo

• https://x.com/Yuz6Yusof/status/1982864787144093994/photo/1

In a cohort of 269,304 IBD patients, NSAID use showed a small increase in IBD-related hospitalisation (HR 1.08), meeting non-inferiority threshold (HR <1.2). No risk in UC (HR 0.96); modest risk in Crohn’s (HR 1.16). Relooks at the current paradigm of blanket NSAID avoidance in https://t.co/O8MWg1BP50

• https://x.com/synovialjoints/status/1982862356670480474/photo/1

56 pts w/tracheobronchial stenosis in GPA, highly frustrating disease manifestation Not surprising to see severe dx & prior intralesional tx assoc with incidence (ie necessity) of tracheal dilation Leflunomide protective? Have others seen this? #ACR @RheumNow Abstr#1596 https://t.co/djJXnAkxnv

• https://x.com/EBRheum/status/1982860846771437709/photo/1